rs748876625
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Screening for three mutations (5382insC, 4154delA and 300T>G) was carried out in 55 breast cancer and 66 ovarian cancer patients, and for two mutations, 5382insC and 4154delA, in 376 unselected patients with any cancer (including 51 breast cancer and 29 ovarian cancers) and 215 women with any gynaecological tumour.
|
15951956 |
2005 |
rs748876625
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We found that an exogenous BRCA1 gene strongly inhibited telomerase enzymatic activity in human prostate and breast cancer cell lines and caused telomere shortening in cell lines expressing wild-type BRCA1 (wtBRCA1) but not a tumor-associated mutant BRCA1 (T300G). wtBRCA1 inhibited the expression of the catalytic subunit (telomerase reverse transcriptase [TERT]) but had no effect on the expression of a subset of other components of the telomerase holoenzyme or on the expression of c-Myc, a transcriptional activator of TERT.
|
14612409 |
2003 |
rs62625308
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In another case, EML4-ALK fusion detected in the primary tumor was associated with ALK G1202R secondary resistance mutation in the post-treatment metastasis.
|
30946933 |
2019 |
rs431825412
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four PIK3CA mutations (p.G106A, p.N345T, p.E545K, and p.E545D) were detected in 3 tumors, 2 of which also harbored TP53 mutations.
|
29505425 |
2018 |
rs1060502346
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole-exome sequencing of a breast cancer from a c.104T>C carrier revealed a second, somatic, truncating mutation affecting PALB2, and the tumor displays hallmark genomic features of tumors with BRCA mutations and HR defects, cementing the pathogenicity of L35P.
|
28319063 |
2017 |
rs786203319
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole-exome sequencing of a breast cancer from a c.104T>C carrier revealed a second, somatic, truncating mutation affecting PALB2, and the tumor displays hallmark genomic features of tumors with BRCA mutations and HR defects, cementing the pathogenicity of L35P.
|
28319063 |
2017 |
rs80357750
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole-exome sequencing of a breast cancer from a c.104T>C carrier revealed a second, somatic, truncating mutation affecting PALB2, and the tumor displays hallmark genomic features of tumors with BRCA mutations and HR defects, cementing the pathogenicity of L35P.
|
28319063 |
2017 |
rs886039920
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole-exome sequencing of a breast cancer from a c.104T>C carrier revealed a second, somatic, truncating mutation affecting PALB2, and the tumor displays hallmark genomic features of tumors with BRCA mutations and HR defects, cementing the pathogenicity of L35P.
|
28319063 |
2017 |
rs397508906
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, two NER mutations (ERCC6-Q524* and ERCC4-A583T), identified in the two most platinum-sensitive tumors, were functionally associated with platinum sensitivity in vitro.
|
25634215 |
2015 |
rs80357091
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 (C8092A, C118T), XPD (Lys751Gln), XRCC1 (Arg399Gln) and XRCC3 (Thr241Met) gene polymorphisms were evaluated on tumour DNA by TaqMan allelic discrimination assay.
|
23549037 |
2013 |
rs80357610
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 (C8092A, C118T), XPD (Lys751Gln), XRCC1 (Arg399Gln) and XRCC3 (Thr241Met) gene polymorphisms were evaluated on tumour DNA by TaqMan allelic discrimination assay.
|
23549037 |
2013 |
rs397509205
|
|
|
0.010 |
GeneticVariation |
BEFREE |
DNA sequencing for E1644X mutation and five BRCA1 exon-11 single nucleotide polymorphisms showed tumor LOH.
|
18311584 |
2009 |
rs80356952
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The PHB 163</span>0 C/T single nucleotide polymorphism was associated with breast cancers with clinical features typical for BRCA1-positive tumours and is deserving of further study.
|
19071013 |
2009 |
rs80357107
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRCA1 variants IVS18+1 G>T (del exon 18) and 5632 T >A (V1838E) were classified as pathogenic, with >99% posterior probability of being deleterious, and tumor histopathology was particularly important for their classification.
|
18375895 |
2008 |
rs28897696
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For A1708E, previously shown to be functionally compromised, analysis of oestrogen receptor, cytokeratin 5/6, and cytokeratin 14 tumour expression data significantly strengthened the prediction of pathogenicity, giving a posterior probability of pathogenicity of 99%.
|
18036263 |
2007 |
rs62625307
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To investigate the potential consequences of somatic heterozygosity for a BRCA1 mutation demonstrably associated with breast carcinogenesis on background somatic mutational burden, we applied the two standard assays of in vivo human somatic mutation to blood samples from a manifesting carrier of the Q1200X mutation in BRCA1 whose tumor was uniquely ascertained through an MRI screening study.
|
18158561 |
2007 |
rs876659253
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The increased rate of tumor formation in MMTV-CHK2-D347A mice, compared with the relatively low incidence in chk2-null mice, provides a model to study modifiers of CHK2-dependent transformation.
|
16488990 |
2006 |
rs1057522527
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The c.1116G>A (1235G>A) nonsense mutation (p.W372X) belongs to the genetic abnormalities detected infrequently in hereditary tumors; the c.3862delG (3981delG) frameshift mutation (p.E1288fsX1306) is a novel gene alteration.
|
15712267 |
2005 |
rs397508838
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The c.1116G>A (1235G>A) nonsense mutation (p.W372X) belongs to the genetic abnormalities detected infrequently in hereditary tumors; the c.3862delG (3981delG) frameshift mutation (p.E1288fsX1306) is a novel gene alteration.
|
15712267 |
2005 |
rs80357468
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The c.1116G>A (1235G>A) nonsense mutation (p.W372X) belongs to the genetic abnormalities detected infrequently in hereditary tumors; the c.3862delG (3981delG) frameshift mutation (p.E1288fsX1306) is a novel gene alteration.
|
15712267 |
2005 |